

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Currently Amended) The isolated nucleic molecule of claim 1, wherein said polynucleotide is SEQ ID NO: 47 ~~selected from any one of SEQ ID NO: 1-85~~ and functional variants thereof.
3. (Currently Amended) The isolated nucleic molecule of claim 2, wherein said functional variant has a sequence identity that is greater than or equal to 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90%, ~~89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, or 60%~~ in sequence to SEQ ID NO: 47 ~~any one of SEQ ID NO: 1-85~~.
4. (Currently Amended) An isolated polynucleotide having a sequence selected from
 - (a) sequences complementary to any of the sequences in claim 2; and
 - (b) sequences that are reverse complements to any of the sequences in claim 2;~~and (c) sequences comprising at least 20 contiguous bases, which hybridizes to any of the polynucleotides of (a) or (b).~~
5. (Currently Amended) The isolated nucleic molecule of claim 2, ~~claim 1~~, wherein said polynucleotide confers xylem-preferred gene expression in a plant cell.
6. (Currently Amended) The isolated nucleic molecule of claim 2, ~~claim 1~~, wherein said polynucleotide is capable of upregulating or downregulating the expression of an operably-linked gene in a plant cell.
- 7-20. (Canceled)